Is DNLI or AURA more profitable?

Denali Therapeutics' return on equity of -52.20% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% Aura Biosciences N/A -78.12% -64.08%

Does the media favor DNLI or AURA?

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 1.26 beat Aura Biosciences' score of 0.19 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BEAM or AURA?

In the previous week, Beam Therapeutics had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Beam Therapeutics and 2 mentions for Aura Biosciences. Beam Therapeutics' average media sentiment score of 0.81 beat Aura Biosciences' score of 0.19 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RCUS or AURA?

In the previous week, Arcus Biosciences had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Arcus Biosciences and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.19 beat Arcus Biosciences' score of 0.09 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, DYN or AURA?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Aura Biosciences N/A N/A -$106.19M -$1.74 N/A

Is DYN or AURA more profitable?

Dyne Therapeutics' return on equity of -58.28% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Aura Biosciences N/A -78.12% -64.08%

Does the media favor DYN or AURA?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 6 mentions for Dyne Therapeutics and 2 mentions for Aura Biosciences. Dyne Therapeutics' average media sentiment score of 1.20 beat Aura Biosciences' score of 0.19 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AURA or TNGX?

In the previous week, Tango Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Tango Therapeutics and 2 mentions for Aura Biosciences. Tango Therapeutics' average media sentiment score of 0.93 beat Aura Biosciences' score of 0.19 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aura Biosciences (AURA) Competitors

$6.88 -0.02 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$6.87 -0.01 (-0.15%)

As of 07:54 PM Eastern

Compare

AURA vs. DNLI, BEAM, RCUS, DYN, and TNGX

Should you buy Aura Biosciences stock or one of its competitors? MarketBeat compares Aura Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aura Biosciences include Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.

How does Aura Biosciences compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Aura Biosciences has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	9.44	-$512.54M	-$2.88	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Denali Therapeutics' return on equity of -52.20% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Aura Biosciences	N/A	-78.12%	-64.08%

92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 12.5% of Denali Therapeutics shares are owned by insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Denali Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 1.26 beat Aura Biosciences' score of 0.19 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics presently has a consensus price target of $34.25, indicating a potential upside of 74.21%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 197.97%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Denali Therapeutics beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Aura Biosciences has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Aura Biosciences	N/A	-78.12%	-64.08%

In the previous week, Beam Therapeutics had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for Beam Therapeutics and 2 mentions for Aura Biosciences. Beam Therapeutics' average media sentiment score of 0.81 beat Aura Biosciences' score of 0.19 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics has higher revenue and earnings than Aura Biosciences. Beam Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.76	-$79.99M	-$0.68	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Beam Therapeutics currently has a consensus price target of $46.83, suggesting a potential upside of 58.49%. Aura Biosciences has a consensus price target of $20.50, suggesting a potential upside of 197.97%. Given Aura Biosciences' higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Beam Therapeutics beats Aura Biosciences on 12 of the 16 factors compared between the two stocks.

How does Aura Biosciences compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aura Biosciences has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Aura Biosciences	N/A	-78.12%	-64.08%

In the previous week, Arcus Biosciences had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Arcus Biosciences and 2 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.19 beat Arcus Biosciences' score of 0.09 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Aura Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aura Biosciences has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.16	-$353M	-$3.18	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Arcus Biosciences currently has a consensus price target of $33.89, indicating a potential upside of 41.90%. Aura Biosciences has a consensus price target of $20.50, indicating a potential upside of 197.97%. Given Aura Biosciences' higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Arcus Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Summary

Arcus Biosciences beats Aura Biosciences on 8 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

In the previous week, Dyne Therapeutics had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 6 mentions for Dyne Therapeutics and 2 mentions for Aura Biosciences. Dyne Therapeutics' average media sentiment score of 1.20 beat Aura Biosciences' score of 0.19 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aura Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Dyne Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Dyne Therapeutics' return on equity of -58.28% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Aura Biosciences	N/A	-78.12%	-64.08%

Dyne Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 94.55%. Aura Biosciences has a consensus target price of $20.50, indicating a potential upside of 197.97%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Dyne Therapeutics beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to Tango Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Aura Biosciences has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

In the previous week, Tango Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Tango Therapeutics and 2 mentions for Aura Biosciences. Tango Therapeutics' average media sentiment score of 0.93 beat Aura Biosciences' score of 0.19 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aura Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Aura Biosciences presently has a consensus price target of $20.50, indicating a potential upside of 197.97%. Tango Therapeutics has a consensus price target of $32.27, indicating a potential upside of 50.32%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Tango Therapeutics has higher revenue and earnings than Aura Biosciences. Tango Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Tango Therapeutics	$62.38M	49.79	-$101.59M	-$0.83	N/A

Summary

Tango Therapeutics beats Aura Biosciences on 11 of the 15 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$713.37M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-3.95	17.78	22.39	24.18
Price / Sales	N/A	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	3.19	6.63	9.84	6.72
Net Income	-$106.19M	$24.20M	$3.57B	$337.19M
7 Day Performance	-10.18%	-3.24%	-1.16%	0.48%
1 Month Performance	-1.85%	0.53%	3.85%	5.07%
1 Year Performance	8.69%	47.24%	27.40%	34.25%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	2.8937 of 5 stars	$6.88 -0.3%	$20.50 +198.0%	+12.0%	$713.37M	N/A	N/A	50
DNLI Denali Therapeutics	3.7179 of 5 stars	$19.38 +4.0%	$34.25 +76.7%	+38.6%	$3.08B	$330.53M	N/A	430	Positive News
BEAM Beam Therapeutics	2.1129 of 5 stars	$29.79 +4.0%	$46.83 +57.2%	+78.9%	$3.06B	$139.74M	N/A	510
RCUS Arcus Biosciences	2.4488 of 5 stars	$24.17 +3.2%	$33.89 +40.2%	+165.3%	$3.04B	$247M	N/A	500
DYN Dyne Therapeutics	3.1019 of 5 stars	$18.15 +4.5%	$35.00 +92.8%	+35.7%	$3.00B	N/A	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. DNLI, BEAM, RCUS, DYN, and TNGX

How does Aura Biosciences compare to Denali Therapeutics?

Summary

How does Aura Biosciences compare to Beam Therapeutics?

Summary

How does Aura Biosciences compare to Arcus Biosciences?

Summary

How does Aura Biosciences compare to Dyne Therapeutics?

Summary

How does Aura Biosciences compare to Tango Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. DNLI, BEAM, RCUS, DYN, and TNGX

How does Aura Biosciences compare to Denali Therapeutics?

Which has stronger earnings and valuation, DNLI or AURA?

Is DNLI or AURA more profitable?

Do insiders & institutionals believe in DNLI or AURA?

Which has more volatility and risk, DNLI or AURA?

Does the media favor DNLI or AURA?

Do analysts recommend DNLI or AURA?

Summary

How does Aura Biosciences compare to Beam Therapeutics?

Is BEAM or AURA more profitable?

Does the media prefer BEAM or AURA?

Which has stronger earnings and valuation, BEAM or AURA?

Do analysts rate BEAM or AURA?

Which has more risk and volatility, BEAM or AURA?

Do institutionals and insiders have more ownership in BEAM or AURA?

Summary

How does Aura Biosciences compare to Arcus Biosciences?

Do institutionals & insiders hold more shares of RCUS or AURA?

Is RCUS or AURA more profitable?

Does the media favor RCUS or AURA?

Which has higher earnings and valuation, RCUS or AURA?

Do analysts rate RCUS or AURA?

Which has more risk & volatility, RCUS or AURA?

Summary

How does Aura Biosciences compare to Dyne Therapeutics?

Does the media favor DYN or AURA?

Do institutionals and insiders believe in DYN or AURA?

Which has preferable valuation and earnings, DYN or AURA?

Which has more volatility & risk, DYN or AURA?

Is DYN or AURA more profitable?

Do analysts rate DYN or AURA?

Summary

How does Aura Biosciences compare to Tango Therapeutics?

Is AURA or TNGX more profitable?

Does the media refer more to AURA or TNGX?

Do insiders and institutionals believe in AURA or TNGX?

Which has more risk & volatility, AURA or TNGX?

Do analysts prefer AURA or TNGX?

Which has better earnings and valuation, AURA or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools